Summary The p53 gene is contained within 16-20 kb of cellular DNA located on the short arm of human chromosome 17 at position 17pl3.1. This gene encodes a 393-amino-acid nuclear phosphoprotein involved in the regulation of cell proliferation. Current evidence suggests that loss of normal p53 function is associated with cell transformation in vitro and development of neoplasms in vivo. More than 50% of human malignancies of epithelial, mesenchymal, haematopoietic, lymphoid, and central nervous system origin analysed thus far, were shown to contain an altered p53 gene. The oncoproteins derived from several tumour viruses, including the SV40 large T antigen, the adenovirus EIB protein and papillomavirus E6 protein, as well as specific cellular gene products, e.g. murine double minute-2 (MDM2), were found to bind to the wild-type p53 protein and presumably lead to inactivation of this gene product. Therefore, the inactivation of p53 tumour suppressor gene is currently regarded as an almost universal step in the development of human cancers. The current data on p53-associated tumourigenesis are briefly discussed in this minireview.
During the past decade, the rapid development of molecular biology lead to recognition that cancers arise as the result of accumulation of genetic alterations that interfere with the normal control of cell growth and differentiation. These events fall mainly into two distinct categories, i.e., the activation of proto-oncogenes and inactivation of tumour suppressor genes (Bishop, 1987; Bos, 1989; Vogelstein, 1990; Cantley et al., 1991) . Proto-oncogenes are normal cellular genes that, when inappropriately activated as oncogenes, cause dysregulation of growth and differentiation pathways and enhance the probability of neoplastic transformation. In contrast to proto-oncogenes, tumour suppressor genes are normal cellular genes, which when inactivated lead to a disturbance of cell proliferation and the development of neoplasias.
Interest was initially focused on oncogenes. The discoveries of tumour suppressor genes such as the p53 gene, retinoblastoma susceptibility gene (RB), the Wilms tumour (WT1) gene, the deleted in colon carcinoma (DCC) gene, the mutated in colorectal carcinoma (MCC) gene, the adenomatous polyposis coli (APC) gene, and the neurofibromatosis type 1 (NF1) gene, have added a new dimension to our understanding of human carcinogenesis (Marshall, 1991; Weinberg, 1991) . These genes have quickly become some of the most intensely studied subjects in cancer research.
So far, the best known gene of this group is the p53 gene. This gene is thought to play an important role in the regulation of cell proliferation, and it has been suggested that the loss of normal p53 function is associated with cell immortalisation or transformation in vitro and development of neoplasms in vivo. The alterations within the coding sequences of the p53 tumour suppressor gene are among the most frequent genetic changes detected in human cancers. The p53 gene or gene product is a common cellular target in human carcinogenesis provoked by physical factors, chemical carcinogens or tumour viruses.
The p53 gene and gene product Miller et al., 1986 ). This gene is composed of eleven exons, the first of which is noncoding and localised 8-10 kb away from the exons 2-11 ( Figure 1 ). The p53 gene has been conserved during evolution. In cross-species comparison, the p53 proteins show five highly (> 90%) conserved regions among the amino acid residues 13 -19, 117-142, 171-181, 234-258, and 270-286 (Figure 1 ) (Soussi et al., 1990) .
The product of p53 gene is a 393-amino-acid nuclear phosphoprotein (about 53 kD in molecular weight). It was first identified as a cellular protein in 1979 because it formed a tight complex with the SV40 large T antigen, and therefore was co-immunoprecipitated with anti-T antibodies from extracts of SV40-transformed cells (Lane & Crawford, 1979; Linzer & Levine, 1979) . The p53 protein was found in very low quantities in normal cells, but larger quantities of p53 (5-100-fold) could be detected in transformed cells in culture and in human tumours.
Function of the p53
The p53 gene was originally regarded as a dominant oncogene because its overexpression resulted in immortalisation of rodent cells, and the p53 gene could transform rat embryo fibroblasts in concert with an activated ras gene (Jenkins et al., 1984; Parada et al., 1984; Rovinski & Benchimol, 1988) . It soon became clear, however, that many of these p53 clones were mutated forms of the gene, and that these mutant alleles have properties different from those of the wild-type p53 gene (Lane & Benchimol, 1990 ). When the above experiments were repeated with the wild-type allele, this allele was found to suppress or inhibit cell transformation in culture mediated by either viral or cellular oncogenes (Eliyahu et al., 1989; Finlay et al., 1989; Hinds et al., 1989) . The murine wild-type p53 gene can suppress the transformation of rat embryo fibroblasts in cell culture by known oncogenes such as ras and adenovirus El B (Eliyahu et al., 1989; Finlay et al., 1989) , and the introduction of the wild-type or cDNA into a transformed cell in culture stops cell growth at the GI phase of the cell cycle (Baker et al., 1990; Chen et al., 1990; Diller et al., 1990) . More importantly, the wild-type p53 gene is capable of reverting the transformed phenotype of human colon (Baker et al., 1990) , bladder (Chen et al., 1990) (Kastan et al., 1992; Lane, 1992) . Emerging evidence also suggests that p53 appears to function normally as a GI-S checkpoint control for DNA damage (Hartwell, 1992; Kastan et al., 1992; Lane, 1992 (Levine et al., 1991) . In mutated p53 proteins, the DNA binding capacity, transcriptional activitor function and initiation of DNA replication are all altered (Lane & Benchimol, 1990; Friedman et al., 1990; Farmer et al., 1992; Hupp et al., 1992; Kern et al., 1992 gene reveal that missense mutations or allelic losses occur frequently in diverse human cancers ; (2) germline mutation of p53 is associated with the LiFraumeni familial cancer syndrome (Frebourg & Friend, 1992) ; (3) loss of normal p53 function increases susceptibility of mice to tumour formation (Lavigueur et al., 1989; Donehower et al., 1992) ; (4) functional inactivation due to formation of protein complexes between the wild-type p53 and oncoproteins of several tumour viruses is linked to tumour virus-mediated oncogenesis (Levine, 1990) ; and (5) binding of the wild-type p53 to specific amplified cellular gene products is associated with the development of certain human malignancies (Oliner et al., 1992) .
Missense mutations and allelic losses of the p53 gene The evolutionarily conserved regions are the most frequent sites of mutations occurring in many human tumours . More than 90% of the substitution mutations reported so far in malignant tumours are clustered between exon 5 and 8 and are localised in four evolutionarily conserved regions (i.e., domains II to V in Figure 1 ). Among these conserved regions, at least four mutation 'hot spots', located at the amino-acid residues 175, 248, 273 and 282, have been identified in a variety of human neoplasms ( Figure  1 ). Mutations in these 'hot spot' codons account for approximately 30% of all p53 mutations. In most tumours, both p53 alleles are inactivated, one through a point mutation, the other through a deletion. In addition, most of these p53 mutations in human cancers are missense mutations, giving rise to an altered protein .
Alterations within the coding sequences of the p53 tumour suppressor gene are currently regarded as the most frequent genetic changes in human cancers. Mutations of the p53 gene are present in all major histogenetic groups. They are found in epithelial, mesenchymal, haematopoietic and lymphoid neoplasms as well as in tumours of the central nervous system Chang et al., 1993) . Approximately one-half of the adult cancers of the colon Nigro et al., 1989; Shaw et al., 1991) stomach (Tamura et al., 1991) , lung Miller et al., 1992) , esophagus Bennett et al., 1992) , breast Callahan et al., 1992) , liver (Bressac et al., 1991; Hsu et al., 1991; Hsia et al., 1992 ), brain Fults et al., 1992) , reticuloendothelial tissues and hematopoietic tissues (Ichikawa et al., 1992; Sugimoto et al., 1992) , analysed so far, contain the mutant p53 gene. It should be pointed out, however, that the association between allelic loss and mutation in cell lines is very strong but much less work has been done on solid tumours and it seems that the incidence of p53 mutations in real life is actually much lower than is seen in vitro (Wright et al., 1991; Effert et al., 1992) . The reported p53 mutations in solid tumours ranged from a high of 70% (possibly 100%) in lung cancers to rare occurrences in thyroid and nasopharyngeal carcinomas (Takahashi et al., 1989; Wright et al., 1991; Effert et al., 1992) . Similarly, in contrast to the reports of a high percentage of p53 gene alteration and overexpression Bartek et al., 1991; Callahan et al., 1992; Porter et al., 1992) , Mazars et al. (1992) looked for p53 mutation in over 90 breast carcinomas and could only find mutations in some 20% of the lesions. Accordingly, the incidences of p53 mutations vary greatly between tumour types, geographical locations, as well as from author to author. At present the reasons for these variations remain unclear. These may stem from the different experimental approaches used and from differences in tumour sampling.
Analysis of the reported p53 mutations revealed significant differences between the tumour types as well as their tissues of origin. Several consistent features were found in the p53 mutation spectra of human cancers: (1) transitions at CpG dinucleotide contribute heavily to the mutation frequency in many cancers. This pattern of mutation may result from spontaneous mutations arising in mammalian cells . (2) A mutation at codon 249 predominates in hepatocellular carcinomas in individuals in the high-incidence regions. Hepatitis B virus (HBV) infection and aflatoxin exposure are probably the responsible factors (Bressac et al., 1991; Hsu et al., 1991; Hsia et al., 1992) . (3) Nonclustered G to T transversions occur frequently in lung, esophageal as well as head and neck cancers. This may reflect a significant influence of exogenous carcinogen-exposure, particularly cigarette smoking and alcohol consumption Puisieux et al., 1991) . (4) The mutations at dipyrimidine sequences, particularly C to T single base mutations and less frequent CC to TT double-base transitions have been significantly associated with ultraviolet radiation and are frequently detected in skin carcinomas. On the other hand, p53 mutational patterns in malignancies of the parenchymal organs do not show these UV-specific mutations (Brash et al., 1991; Kress et al., 1992) . Therefore, analysis of the p53 mutations may provide clues to the etiology of these diverse tumours and to the function of specific regions of p53.
Because of its short half-life of about 6-20 min, wild-type p53 does not normally accumulate in amounts detectable by conventional immunoprecipitation of immunohistochemical methods. However, many missense mutations induce changes which prolong the half-life of the p53 protein up to 6 h (Levine et al., 1991) . Therefore, a detectable protein usually means mutation, and detection of p53 overexpression by immunohistochemical techniques is currently used as an indirect indicator of p53 mutations. More than half of human malignancies tested so far have been shown to overexpress the p53 protein (Bartek et al., 1991; Gusterson et al., 1991; Porter et al., 1992) . There are reports of increasing immunostaining intensity with increasing progression of neoplasia in surgical samples (Allred et al., 1993; Bell et al., 1993; Kakeji et al., 1993) .
Point mutations in the p53 gene, however, is not the only mechanism by which the p53 protein can be stabilised. As it will be discussed later, the normal p53 protein can be stabilised by the action of viral gene products (SV40 large T antigen, the adenovirus ElB protein and papillomavirus E6 protein). Furthermore, there is also some evidence to suggest that p53 stability is affected by cellular proteins, for example, MDM2. Treatment of cells with DNA-damaging agents such as UV light, UV mimetic drugs, and -y irradiation has also been shown to increase the level and stability of the p53 protein (Lu et al., 1992; Hall et al., 1993) . Therefore, great caution should be paid in the interpretation of immunohistochemically positive staining as representing p53 gene mutation (Wynford-Thomas, 1992) .
Germline mutation of p53 and Li-Fraumeni syndrome The Li-Fraumeni syndrome is a rare familial cancer syndrome characterised by diverse mesenchymal and epithelial neoplasms at multiple sites (Li et al., 1988; Garber et al., 1991) . The spectrum of cancers in this syndrome includes breast carcinomas, soft tissue sarcomas, brain tumours, osteosarcoma, leukaemia, adrenocortical carcinoma, and possibly other tumours. Tumours develop in the family members at unusually early ages, and multiple primary tumours are frequent (Li et al., 1988; Garber et al., 1991) .
Transmission of the Li-Fraumeni syndrome is autosomal dominant and the clinical definition requires; (a) an individual (the proband) with a sarcoma diagnosed before age 45; (b) a first degree relative with cancer before age 45; and (c) another first or second degree relative with either a sarcoma diagnosed at any age or any cancer diagnosed under 45 (Li et al., 1988; Garber et al., 1991) . The relative risk of cancer in Li-Fraumeni patients during childhood has been estimated to be 20 (Garber et al., 1991) .
Germinal mutations of the p53 gene were first identified in several families with the Li-Fraumeni syndrome in 1990 (Malkin et al., 1990 Furthermore, all the tumour-affected individuals retain the mutant allele and lose the wild-type p53 allele in their tumour tissues (Malkin et al., 1990) . These phenomena are consistent with the genetic changes of the RB gene in familial forms of retinoblastoma, and could well be explained by the 'two hit' hypothesis presented by Knudson (1971) . It is therefore thought that the Li-Fraumeni syndrome patients are predisposed to cancer because one p53 allele is inactivated in the germline and only the remaining allele needs to be altered by somatic mutation. In normal individuals developing a sporadic tumour however, both p53 alleles must be inactivated in the same cell by somatic mutation.
The first germline mutations described were found in codons 245 and 258 within one of the evolutionary conserved domains (Malkin et al., 1990) . Later, the analysis of germline mutations in the Li-Fraumeni syndrome clearly indicated that they are widely distributed among the p53 gene (Srivastava et al., 1990; Law et al., 1991; Santibanez-Koref et al., 1991) . Most of the germline mutations reported so far are missense mutations located in the evolutionarily conserved domains. It should be pointed out that germline mutations for p53 have not been found in all Li-Fraumeni syndromelike families (Santibanez-Koref et al., 1991; Birch, 1992; Frebourg & Friend, 1992) . These negative results must be analysed with caution. Analysis of the entire p53 gene sequence in these cases are apparently required. Alternatively, it is possible that germline p53 mutations are not the only molecular basis of the Li-Fraumeni syndrome. For example, genetic alterations affecting proteins in the p53 signalling pathway could produce phenotypes identical to the Li-Fraumeni syndrome (Barnes et al., 1992; Frebourg & Friend, 1992; Oliner et al., 1992) .
The discovery of mutations in the tumour suppressor genes that occur not only at the somatic level but also in the germline has important clinical implications. Detection of such germline mutations should allow identification of subjects at high-risk to develop cancers . Recently, germline p53 mutations were also found in some patients who had an unusual history of cancers (e.g., multiple malignancies and a family history of cancers), but whose family histories are not fully indicative of the Li-Fraumeni syndrome (Malkin et al., 1992; Sameshima et al., 1992; Toguchida et al., 1992) . The early detection of such mutations would be useful not only in treating these patients, but also in identifying family members who may be at high-risk for the development of tumours.
Tumour formation in transgenic mice
The involvement of p53 in the development of cancers was also demonstrated in vivo by generating transgenic mice carrying mutated p53 genomic fragments (Lavigueur et These results demonstrated that the introduction into the mouse germ line of abnormal p53 genes results in markedly elevated tumour susceptibility and provide direct evidence that p53 plays a causal role in tumour formation. The long latency period for tumour induction and the overall tumour incidence, however, suggested that alterations of the p53 gene alone may not be sufficient for tumour development and that further genetic or epigenetic changes might be required. Similar to the observations in human beings, the variety of tumours identified in the transgenic mice indicate that p53 is involved in the tumourigenesis of many tissues and cell types. The experimental results also indicate that the p53 protein plays an important role in the regulation of cell growth, but does not have an important function in the mouse development and differentiation. This in contrast to the RB tumour suppressor gene, which has been recently shown to be essential for normal mouse development (Clarke et al., 1992; Jacks et al., 1992; Lee et al., 1992) .
It was recently noted (Donehower et al., 1992) that fibroblasts derived from the homozygous animals became immortalised in tissue culture much more readily than cells from either the heterozygote or wild-type mice. Thus, the loss of p53 function is closely correlated with the immortalisation of cells in tissue culture.
Interaction of wild-type p53 with oncoprotein of tumour viruses
In addition to the missense mutations that cause inactivation of p53, an alternative mechanism for inactivation of the wild-type p53 is to bind to the transforming proteins of DNA tumour viruses (Levine, 1991) . It has been demonstrated that the SV40 large T antigen (Tan et al., 1986; Schmeig et al., 1988) , the adenovirus E1B protein (Sarnow et al., 1982) and papillomavirus E6 protein (Scheffner et al., 1990; bind to the p53 protein (Figure 2) . Similarly, the SV40 large T antigen (Decaprio et al., 1988) , the adenovirus EIA protein (Whyte et al., 1988) and papillomavirus E7 protein (Dyson et al., 1989; Muinger et al., 1989) bind to the RB protein (Figure 2) . Binding of p53 to SV40 large T or adenovirus E1B proteins leads to an increased half-life of p53 and presumably inactivates its normal function by formation of stable complexes. In contrast, E6 proteins from papillomaviruses are known to facilitate the degradation of p53 (Scheffner et al., 1990; Werness et al., 1990) . Accordingly, cancers resulted from tumour virus infections may contain only wild-type p53 allele. In this regard, cervical carcinomas could be particularly instructive. Human papillomaviruses (HPVs), especially HPV types 16 and 18, have been implicated as important etiological factors in the development of human cervical cancer (Syrjiinen et al., 1987; Chang, 1990; Howley, 1991; zur Hausen, 1991) . More than 90% of cervical carcinomas contain detectable HPV DNA sequences, many of which constantly express the E6 open reading frame (Howley, 1991) . While the E6 proteins from HPV 16 and 18 bind to p53, the E6 proteins from HPV types 6 and 11 fail to bind with p53 to a detectable extent (Scheffner et al., 1990; Werness et al., 1990 (Momand et al., 1992 (1992) isolated the human homologue of MDM2, mapped it to the long arm of human chromosome 12, and showed that it also can bind to p53. As is the case with the tumour viruses, this binding appears to inhibit the ability of p53 to transactivate genes adjacent to p53-binding sites (Momand et al., 1992) . The MDM2 protein was recently found to be able to overcome the growth-suppressive properties of wild-type p53; and overexpression of the MDM2 protein resulted in the immortalisation and transformation of primary rat embryo fibroblasts (Finlay, 1993) .
It has been demonstrated that the MDM2 gene is often amplified in human sarcomas (Oliner et al., 1992) . This is consistent with the previous demonstration of chromosomal aberrations at this site in these tumours. Therefore, high numbers of MDM2 gene copies and the consequent overexpression of the MDM2 protein may, like tumour virus oncoproteins, inactivate normal p53 functions by complexing to it.
Mechanisms involved in p53 inactivation
The reasons for tissue-specific mutations of the p53 gene are unknown. These differences may reflect variable constraints imposed by the biological characteristics of different tissues or exposure to different types of carcinogens (Cohen & Ellwein, 1991; Harris, 1991; Strauss, 1992) . Differences in metabolic and DNA repair capacities in different tissues and cell types are some of the factors expected to underline these differences. Typical base changes in characteristic locations can be related to molecular mechanisms such as covalent binding of DNA bases by electrophilic carcinogen metabolites. Endogenous mechanisms, e.g. DNA polymerase infidelity, depurination, oxidative damage from free radicals generated by biological processes, and deamination of 5-methylcytosine can also lead to mutations (Harris, 1991; Strauss, 1992) . Of the known exogenous carcinogens, many elicit base substitutions in bacteria, mammalian cells in vitro and in experimental animals (Harris, 1991; Strauss, 1992) . This activity has been used in short-term tests to identify candidate carcinogens. Electrophilic attack of DNA bases by carcinogen metabolites, followed by fixation of the damage at the site of the adducted base during DNA replication has been the principal model of action. Ample biochemical data exist on the adducts and specific base substitutions expected from electrophilic metabolites of various important classes of carcinogens, including N-nitrosamines, polycyclic aromatic hydrocarbons, and fungal toxins, being consistent with the results of animal experiments on the specificity of tumour mutations in ras. The mechanisms of p53 inactivation due to the formation of protein complexes between viral oncoprotein or cellular gene product and wild-type p53 protein, differ considerably from those elicited by gene alterations. Tumours resulted from this pathway may contain only wild-type p53. Notable examples include cervical carcinomas associated with HPV infection, and sarcomas with MDM2 amplification. In both cervical carcinoma (Crook et al., 1991; Scheffner et al., 1991) and sarcomas with MDM2 amplification (Oliner et al., 1992) , p53 mutations appear to be rare, whereas such mutations are common in other anogenital malignancies which are not associated with tumour virus infections, and sarcomas without MDM2 amplification.
A model for p53-associated tumourigenesis The molecular mechanisms by which the p53 is involved in tumourigenesis are not fully understood. Based on recent data, Vogelstein and Kinzler (1992) proposed a model for p53 gene and gene product function in cell growth control. In this model, the wild-type p53 gene binds to p53-binding sites as a tetramer and stimulates the expression of downstream genes that negatively control cell growth (Stenger et al., 1992; . Under normal conditions, the wild-type p53 appears to play little part in cell cycle control. However, when cells or cellular DNA are damaged, the cells increase p53 expression. The accumulation of wild-type p53 switches off the cell cycle until the damage is repaired. If the repair fails, p53 may further trigger controlled cell death through apoptosis (Lane, 1992; . On the other hand, cells with p53 allelic losses or with mutant p53 genes are only partially blocked, and therefore acquire a selective growth advantage . Clonal expansion of these cells, in combination with the inactivation of other tumour suppressor genes and/or activation of certain oncogenes as well as other genetic changes in the cell, may lead to tumour formation and progression. Consistent with this hypothesis, recent results show that loss of wild-type p53 leads to gene amplification at Physical factors * radiation * UV-light * X-ray p53 mutation or allelic loss high frequency and enhances the possibility of genomic rearrangements (Livingstone et al., 1992; Yin et al., 1992) . The enhanced genomic instability may, therefore, accelerate the occurrence of certain genetic changes that permit cells to overcome the normal strictures against excessive multiplication and metastasis and lead to tumour formation and progression.
As shown in Figure 3 , loss of normal p53 function could be achieved in a variety of ways, including genetic changes in the p53 gene (e.g., germline mutations, somatic mutation, small or large deletions, structural rearrangements, and genomic insertions), formation of protein complexes with viral oncoproteins (e.g., the SV40 T antigen, adenovirus ElB, and papillomavirus E6), and binding to the cellular gene products (e.g., MDM2). Therefore, analysis of the p53 gene and gene product in tumour cells may reveal significant differences in its involvement between stages of tumorigenesis, tumour types as well as their tissues of origin . In some tumours, a loss of one or both p53 alleles may occur, which reduces the concentration of p53 tetramers below that required to perform their normal function. In other tumours, a nonsense mutation results in the truncation of p53. More commonly, one allele of p53 develops a missense mutation, and this is accompanied by a deletion of the other allele, resulting in the absence of any wild-type p53 tetramers. This occurs in many tumours, including those of the colon, brain, lung, liver, esophagus, and bladder. In cervical cancers, the expression of HPV E6 results in the functional inactivation of the p53 through binding and degradation. In soft-tissue sarcoma, the amplification of MDM2 and the binding of its products to p53 creates a similar loss of functional p53.
These data support the notion that p53 is a common cellular target in human carcinogenesis mediated by endogenous factors and exogenous carcinogens as well as tumour viruses. 
